Skip to main content
. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355

Figure 2.

Figure 2.

Rate of ADAbs formation to (a) IFX and (b) ADM.

Note: circled data point indicates study excluded from analysis as it had a small sample size (n = 28) and a high rate of immunogenicity (79%).

ADAbs, anti-drug antibodies; ADM, adalimumab; IFX, infliximab; LTE, long-term extension; n, number; RCT, randomized controlled trial.